Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets open firm
Fri, 4 Jul 09:30 am

The major Asian stock markets have opened on a mixed note with stock markets in Singapore (up 0.2%) and Japan (up 0.5%) leading the gains. However, the stock markets in South Korea (down 0.1%) and Taiwan (down 0.1%) have opened in the red.

The Indian share markets have opened the day on a positive note. Barring metal and capital goods, all sectoral indices have opened in the green.

The Sensex today is up by around 33 points (0.1%), while the NSE-Nifty is up by around 9 points (0.1%). The midcap and smallcap stocks have also opened in the green with BSE Mid Cap and BSE Small Cap indices up by around 0.5%nd 0.6 respectively. The rupee is currently trading at Rs 59.66 to the US dollar.

Steel stocks have opened the day mainly in the green with Jindal SAW Ltd and Tata Sponge Ltd leading the gains. However, Tayo Rolls Ltd and Steel Authority of India Ltd were facing selling pressure. As per a leading financial daily, the Modi government is likely to sell a 5% stake in state-run Steel Authority of India Ltd (SAIL) in the last week of this month thus kicking off what is set to be a busy divestment schedule. Sources related to the development have suggested that the marketing road shows for the stake sale valued at about US$340 m ( at current market prices) will begin soon after the presentation of the federal budget on July 10, 2014. Post the sale, the government's holding in the company would come down to 75 %. SAIL's disinvestment, if completed, would be the first of a series of asset disposals that are estimated to raise an amount of Rs 600-800 bn in FY15.

Indian Pharma stocks have opened the day mainly in the green with Orchid Chemicals Ltd and Strides Arocolab Ltd leading the gains. As per a leading financial daily, Glenmark Pharmaceuticals Ltd has announced that its new molecule - a novel monoclonal antibody for potential treatment of autoimmune diseases is entering human trials. Monoclonal antibodies are produced by a single clone of cells grown in culture to produce unlimited quantities of identical antibodies. They are used in diagnosis, therapy and biotechnology. There are more than 80 autoimmune disorders including rheumatoid arthritis and multiple sclerosis. The company has completed the Phase I enabling preclinical development programme for its novel monoclonal antibody GBR 830, and has filed a Phase I clinical trial application with The Netherlands authorities. With this, the company now has three monoclonal antibodies in clinical development.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.